Copyright
©The Author(s) 2017.
World J Diabetes. Jul 15, 2017; 8(7): 381-389
Published online Jul 15, 2017. doi: 10.4239/wjd.v8.i7.381
Published online Jul 15, 2017. doi: 10.4239/wjd.v8.i7.381
Table 14 Change in HbA1c % before and after autologous bone marrow derived stem cell therapy in Group II
| Patient | Baseline | 3 mo | 6 mo | 12 mo | 18 mo |
| 1 | 7 | 7.1 | 7 | 7.4 | 6.5 |
| 2 | 6.2 | 6.4 | 6.5 | 6.7 | 7.7 |
| 3 | 6.6 | 6.5 | 6.5 | 6.5 | - |
| 4 | 5.6 | 7.5 | 7 | 6.4 | - |
| 5 | 6.6 | 6.7 | 6.5 | - | - |
| 6 | 6.4 | 6.3 | - | - | - |
| 7 | 6.5 | 5.7 | - | - | - |
| Mean ± SE | 6.4 ± 0.16 | 6.6 ± 0.21 | 6.7 ± 0.12 | ||
| P value | 0.573 | 0.351 |
- Citation: Sood V, Bhansali A, Mittal BR, Singh B, Marwaha N, Jain A, Khandelwal N. Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus - defining adequate administration methods. World J Diabetes 2017; 8(7): 381-389
- URL: https://www.wjgnet.com/1948-9358/full/v8/i7/381.htm
- DOI: https://dx.doi.org/10.4239/wjd.v8.i7.381